WASHINGTON , Aug. 1, 2022 /PRNewswire/ -- Kidney Care Partners (KCP) – the nation's largest non-profit, non-partisan coalition of more than 30 organizations representing patients, professional care providers, and a wide range of kidney care stakeholders – applauded the introduction of the bipartisan bill in the U.S. House of Representatives, H.R. 8594, to amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act. Sponsored by Representatives Yvette Clarke (D-NY), Jodey Arrington (R-TX), Buddy Carter (R- GA) and Danny Davis (D-IL), the legislation, if passed, would restore protections intended by Congress in the original enactment of the language at issue in the Medicare Secondary Payor Act and ensure individuals living with end stage renal disease (ESRD) – or kidney failure -- cannot be discriminated against based on their need for dialysis.
"KCP thanks Representatives Clarke, Arrington, Carter and Davis for their leadership on this bill and for acting quickly to address the troubling efforts of private insurers to force individuals requiring dialysis care out of their preferred plan," said Michele Kimball , executive director of KCP. "This legislation will prevent harm to these vulnerable individuals by eliminating any distinction among patients by insurers based on their need for dialysis care, which we believe was always the true intent of the Medicare Secondary Payer Act. It will also help to reinforce the Medicare Part A Trust Fund, which is increasingly underfunded."
"As someone who has personally and painfully experienced the limitations of Medicare when needing a new wheelchair, I applaud this effort to protect a patient's right to choose the best coverage option for themselves," said Dialysis Patient Citizens (DPC) Board of Directors President Andrew Conkling . "Preserving an individual's right to continue their private insurance plan allows for continuity of care and creates an incentive for insurers to cover detection and treatment of chronic kidney disease. Detection and care for early kidney disease can help delay the need for dialysis- ultimately creating cost savings and improving outcomes. Passage of H.R. 8594 would be a win not just for those already living on dialysis but for any American living with or at risk of kidney disease."
Earlier this year, KCP expressed concern that health plans discriminated against those with end-stage renal disease (ESRD) by limiting coverage of life-sustaining treatment, ultimately driving patients to drop their private group coverage, many of which included additional financial protections for both them and their families, in favor of Medicare. This issue was recently considered by the Supreme Court in the Marietta Memorial Hospital Employee Benefit Health Plan v. DaVita case.
"Fundamentally, this is a coverage and cost issue – one that directly impacts patients' ability to afford needed kidney care while further reducing equity among patients in accessing it. Passage of H.R. 8594 will once and for all prevent insurers from pushing dialysis patients prematurely from private insurance into the Medicare program. Its' passage would be a win for patients and the American taxpayer, and KCP urges Congress to act swiftly on this important measure," Kimball concluded.
View original content:https://www.prnewswire.com/news-releases/nations-kidney-community-applauds-introduction-of-bipartisan-legislation-to-protect-insurance-access-for-individuals-living-with-kidney-failure-301597038.html
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing Phase 1/2 trial of 4D-310 for Fabry disease. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. SVB Securities cuts 4D Molecular to Market Perform from Outperform with a price target of $12, down from $28 after the Fabry update. The analyst feels this decision is an
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
Vedanta, a microbiome startup that raised $68 million just over a year ago is letting about 20% of its staff go.
Concentrating for long periods fills our brains with fatigue-inducing toxins – so what can we do about it? By Imy Brighty-Potts.
The new guidelines from the Atlanta-based CDC loosen recommendations for people with direct exposure to the virus. It no longer recommends immediate quarantine.
The latest guidance aligns with the recommendations set for those who are up to date on their COVID-19 vaccines
With CDC relaxing COVID-19 guidelines, you can still shop KN95 face masks for better protection—shop face masks from Amazon, Maskc, Vida and more.
Palm Springs resident Kyle Wilkins received a Jynneos vaccine then noticed sores and other typical monkeypox symptoms two days later.
Anne Heche remains in critical condition as police investigate her for a felony DUI.
Zantac, also sold as ranitidine, was pulled from the market in 2020 following a study that suggested it contained a cancer-causing impurity.
The nation's top public health agency relaxed its COVID-19 guidelines Thursday, dropping the recommendation that Americans quarantine themselves if they come into close contact with an infected person. The Centers for Disease Control and Prevention also said people no longer need to stay at least 6 feet away from others. “The current conditions of this pandemic are very different from those of the last two years,” said the CDC's Greta Massetti, an author of the guidelines.
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.